Videos

Gabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.

Benjamin P. Levy, MD, medical director of thoracic medical oncology for Mount Sinai Health Systems and the associate medical director of the cancer clinical trials office for Mount Sinai Hospital, New York, discusses the tools currently available for predicting mortality risk in patients with early stage lung cancer.

Mikhail Fedyanin, MD, medical oncologist, Russian Academy of Medical Sciences, Moscow, discusses some of the factors associated with discordance in mutation status in metastatic colorectal cancer during the 2016 ESMO Congress.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses when to perform a prophylactic bilateral oophorectomy on a patient who does not have ovarian cancer, but has a known BRCA mutation.

Advanced Colorectal Cancer with Michael Morse, MD

Advanced Colorectal Cancer with Michael Morse, MD

Roy S. Herbst, MD, PhD, discusses the immunotherapy combinations under investigation in NSCLC during the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology.

Gary D. Steinberg, MD, discusses how medical oncologists can benefit from the new American Urological Association guidelines when treating bladder cancer.

Marco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the significant need for new agents to treat MDS.

Barbara Ann Burtness, MD, professor of medicine, Clinical Research Program Leader, Head and Neck Cancers Program and Co-Director, Developmental Therapeutics Research Program at Yale Cancer Center, discusses the ongoing trials looking at immunotherapy as a first-line treatment in head and neck cancer.

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses the need for better surrogate parameters for overall survival in colorectal cancer.

Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center, and Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, discusses the potential role of immunotherapy in the management of breast cancer.

Nitin Jain, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, discusses the checkpoint inhibitors under investigation in chronic lymphocytic leukemia (CLL).

Heinz Gisslinger, MD, Medical University of Vienna, discusses differences between polycythemia vera (PV) and essential thrombocythemia (ET).

MCD with David Fajgenbaum, MD, MBA, Msc

MCD with David Fajgenbaum, MD, MBA, Msc